All News

OncobiotaLUNG, a novel liquid biopsy that detects lung cancer, now has a breakthrough device designation from the FDA.

The investigational drug CFI-402257 alone and in combination with fulvestrant received fast track designation from the FDA for patients with estrogen receptor–positive, HER2-negative advanced breast cancer.

During the 2022 Society for Urologic Oncology (SUO) Annual Meeting, an expert from the Baylor College of Medicine, discussed how perceptions around the use of testosterone therapy have evolved for patients with metastatic prostate cancer.

In a population of patients with patients with mantle cell lymphoma and follicular lymphoma, zandelisib plus zanubrutinib did not increase the rate or severity of class-related adverse effects.

Azeliragon was first evaluated in a group of patients with Alzheimer’s disease prior to being assessed in patients with glioblastoma, a fast-growing and aggressive brain tumor.

Adding the investigational oral drug BXCL701 to pembrolizumab appears effective in small cell neuroendocrine metastatic castration-resistant prostate cancer, a rare and aggressive disease.

Data from a meta-analysis suggest that single-fraction stereotactic ablative body radiotherapy could result in a lower incidence of local failure than multifractionated radiation in patients with renal cell carcinoma.

Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota discusses the incidence of complications and patient-reported outcomes associated with breast conservation therapy for multiple ipsilateral breast cancer.

Lenalidomide plus rituximab consolidation therapy prior to bendamustine/rituximab induction did not significantly improve progression-free survival in patients with mantle cell lymphoma in the phase 2 NCTN E1411 trial.

The National Medical Products Administration of China gives approval to mobocertinib for patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

The use of cobimetinib was effective in patients with Rosai-Dorfman disease, and responses were especially deep in those with KRAS or MEK alterations, according to findings from a recent retrospective study.

An expert from the Mayo Clinic notes that there’s also a great amount of interest in further optimizing the dose of radiation after mastectomy, especially in patients with breast cancer immediately following reconstruction.

A contingent of patients with a type of lung cancer and breast cancer continues to experience responses to treatment with zotatifin, according to updated study findings.

Patients with metastatic prostate cancer and dysphagia or difficulty swallowing may benefit from TAVT-45 compared with abiraterone acetate tablets.

A stool-based, non-invasive, at-home colorectal cancer and advanced adenoma test showed a strong ability to detect disease, according to updated trial results.

Findings from the phase 1b/2 NEXICART-1 study indicated that NXC-201 produced complete responses in 6 evaluable patients with relapsed or refractory AL amyloidosis.

Hypofractionated—large doses of radiation given over a shorter period of time than standard radiation—and conventional proton radiotherapy yielded comparable normal tissue sparing and complication rates postmastectomy in patients with breast cancer, according to findings from a recent study.

Findings from the phase 3 INTRIGUE trial highlighted improved median progression-free survival in patients with KIT exon–mutated gastrointestinal stromal tumors compared with sunitinib.

Data from the phase 2 FIREFLY-1 trial indicated that tovorafenib yielded responses among pretreated patients with recurrent or progressive pediatric low-grade glioma.

The overall survival improvements were observed when tumor-treating fields were combined with immune checkpoint inhibitors with a positive trend towards improvement when combined with docetaxel in those with stage IV non–small cell lung cancer.

Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota indicated that breast conservation therapy, if it can be proven as a reasonable option for patients with multiple ipsilateral breast cancer, could offer patients more choice in treatment.

Imetelstat demonstrated clinically meaningful and statistically significant improvement in transfusion independence at 24 weeks among patients with myelodysplastic syndrome in the phase 3 IMerge trial.

If feasible, hypofractionated radiation—large doses of radiation given over a shorter period of time than standard radiation—after mastectomy would provide more patients with breast cancer a tissue-sparing option, according to an expert from the Mayo Clinic.

It takes a team of physicians from multidisciplinary backgrounds to best manage patients with contralateral breast cancer, according to a Mayo Clinic Expert.

The biologic license application for glofitamab for managing relapsed or refractory large B-cell lymphoma is supported by findings from the phase 1/2 NP30179 study.

Japanese patients with relapsed/refractory large B-cell lymphoma can now receive treatment with axicabtagene ciloleucel following its approval.

Among patients with metastatic pancreatic ductal adenocarcinoma, mitazalimab plus chemotherapy yielded a positive objective response rate in the phase 2 OPTIMIZE-1 trial.

Patients with previously untreated, locally advanced or metastatic urothelial carcinoma responded to treatment with trilaciclib and avelumab.

The biologic license application for cosibelimab for patients with metastatic or locally advanced cutaneous squamous cell carcinoma is supported by findings from a phase 1 study.

BT8009 monotherapy, which received fast track designation from the FDA, may be beneficial for adult patients with locally advanced or metastatic urothelial cancer.